Becton, Dickinson and Company (NYSE:BDX) Shares Bought by Busey Bank

Busey Bank lifted its holdings in shares of Becton, Dickinson and Company (NYSE:BDX) by 3.8% in the 4th quarter, Holdings Channel.com reports. The institutional investor owned 66,255 shares of the medical instruments supplier’s stock after buying an additional 2,399 shares during the quarter. Busey Bank’s holdings in Becton, Dickinson and Company were worth $15,031,000 as of its most recent filing with the SEC.

A number of other hedge funds and other institutional investors have also recently made changes to their positions in BDX. State Street Corp grew its stake in shares of Becton, Dickinson and Company by 0.8% in the 3rd quarter. State Street Corp now owns 13,953,116 shares of the medical instruments supplier’s stock valued at $3,364,096,000 after purchasing an additional 106,616 shares during the last quarter. Geode Capital Management LLC lifted its holdings in shares of Becton, Dickinson and Company by 1.8% during the third quarter. Geode Capital Management LLC now owns 6,285,513 shares of the medical instruments supplier’s stock worth $1,510,050,000 after purchasing an additional 111,101 shares during the period. Massachusetts Financial Services Co. MA grew its position in Becton, Dickinson and Company by 9.4% in the 3rd quarter. Massachusetts Financial Services Co. MA now owns 5,365,554 shares of the medical instruments supplier’s stock valued at $1,293,635,000 after buying an additional 460,440 shares during the last quarter. Charles Schwab Investment Management Inc. raised its position in Becton, Dickinson and Company by 79.0% during the 3rd quarter. Charles Schwab Investment Management Inc. now owns 2,986,543 shares of the medical instruments supplier’s stock worth $720,089,000 after buying an additional 1,317,723 shares during the last quarter. Finally, Nordea Investment Management AB lifted its stake in shares of Becton, Dickinson and Company by 31.0% in the 4th quarter. Nordea Investment Management AB now owns 2,844,566 shares of the medical instruments supplier’s stock worth $647,082,000 after acquiring an additional 673,568 shares during the period. Hedge funds and other institutional investors own 86.97% of the company’s stock.

Insider Activity

In other Becton, Dickinson and Company news, EVP Michael David Garrison sold 2,838 shares of the stock in a transaction on Thursday, December 19th. The stock was sold at an average price of $223.33, for a total transaction of $633,810.54. Following the transaction, the executive vice president now owns 6,141 shares of the company’s stock, valued at $1,371,469.53. This represents a 31.61 % decrease in their position. The sale was disclosed in a document filed with the SEC, which is available through this link. Also, EVP David Shan sold 500 shares of the company’s stock in a transaction on Tuesday, January 21st. The shares were sold at an average price of $240.00, for a total value of $120,000.00. Following the completion of the transaction, the executive vice president now owns 5,741 shares of the company’s stock, valued at $1,377,840. The trade was a 8.01 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold 9,844 shares of company stock worth $2,210,716 over the last three months. 0.36% of the stock is currently owned by corporate insiders.

Analysts Set New Price Targets

Several research analysts recently issued reports on the stock. StockNews.com cut shares of Becton, Dickinson and Company from a “buy” rating to a “hold” rating in a report on Wednesday, December 18th. Piper Sandler lifted their price target on Becton, Dickinson and Company from $275.00 to $280.00 and gave the company an “overweight” rating in a research note on Tuesday. One investment analyst has rated the stock with a hold rating and seven have given a buy rating to the company. According to data from MarketBeat, the company presently has a consensus rating of “Moderate Buy” and a consensus price target of $283.00.

Becton, Dickinson and Company Stock Down 0.9 %

Becton, Dickinson and Company stock opened at $246.85 on Thursday. The firm has a market capitalization of $71.59 billion, a price-to-earnings ratio of 41.56, a price-to-earnings-growth ratio of 1.72 and a beta of 0.39. The company has a debt-to-equity ratio of 0.69, a quick ratio of 0.74 and a current ratio of 1.17. Becton, Dickinson and Company has a fifty-two week low of $218.75 and a fifty-two week high of $250.91. The stock’s fifty day moving average is $229.10 and its two-hundred day moving average is $233.46.

Becton, Dickinson and Company (NYSE:BDX) last posted its earnings results on Thursday, November 7th. The medical instruments supplier reported $3.81 earnings per share for the quarter, beating the consensus estimate of $3.77 by $0.04. The firm had revenue of $5.44 billion during the quarter, compared to the consensus estimate of $5.38 billion. Becton, Dickinson and Company had a net margin of 8.55% and a return on equity of 14.89%. The firm’s revenue for the quarter was up 6.9% on a year-over-year basis. During the same period last year, the firm posted $3.42 EPS. Analysts predict that Becton, Dickinson and Company will post 14.42 EPS for the current fiscal year.

Becton, Dickinson and Company announced that its board has initiated a stock buyback program on Tuesday, January 28th that authorizes the company to repurchase 10,000,000 outstanding shares. This repurchase authorization authorizes the medical instruments supplier to repurchase shares of its stock through open market purchases. Shares repurchase programs are usually a sign that the company’s board believes its shares are undervalued.

Becton, Dickinson and Company Dividend Announcement

The business also recently declared a quarterly dividend, which will be paid on Monday, March 31st. Stockholders of record on Monday, March 10th will be issued a $1.04 dividend. The ex-dividend date of this dividend is Monday, March 10th. This represents a $4.16 dividend on an annualized basis and a dividend yield of 1.69%. Becton, Dickinson and Company’s dividend payout ratio (DPR) is 70.03%.

Becton, Dickinson and Company Profile

Becton, Dickinson and Company develops, manufactures, and sells medical supplies, devices, laboratory equipment, and diagnostic products for healthcare institutions, physicians, life science researchers, clinical laboratories, pharmaceutical industry, and the general public worldwide. The company operates in three segments: BD Medical, BD Life Sciences, and BD Interventional.